Skip to main content
Top

09-09-2017 | Head and neck cancers | Article

Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old

Journal: Radiation Oncology

Authors: Salman A. Eraj, Mona K. Jomaa, Crosby D. Rock, Abdallah S. R. Mohamed, Blaine D. Smith, Joshua B. Smith, Theodora Browne, Luke C. Cooksey, Bowman Williams, Brandi Temple, Kathryn E. Preston, Jeremy M. Aymard, Neil D. Gross, Randal S. Weber, Amy C. Hessel, Renata Ferrarotto, Jack Phan, Erich M. Sturgis, Ehab Y. Hanna, Steven J. Frank, William H. Morrison, Ryan P. Goepfert, Stephen Y. Lai, David I. Rosenthal, Tito R. Mendoza, Charles S. Cleeland, Kate A. Hutcheson, Clifton D. Fuller, Adam S. Garden, G. Brandon Gunn, MD Anderson Head and Neck Cancer Symptom Working Group

Publisher: BioMed Central

Abstract

Background

Given the potential for older patients to experience exaggerated toxicity and symptoms, this study was performed to characterize patient reported outcomes in older patients following definitive radiation therapy (RT) for oropharyngeal cancer (OPC).

Methods

Cancer-free head and neck cancer survivors (>6 months since treatment completion) were eligible for participation in a questionnaire-based study. Participants completed the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN). Those patients ≥65 years old at treatment for OPC with definitive RT were included. Individual and overall symptom severity and clinical variables were analyzed.

Results

Of the 79 participants analyzed, 82% were male, 95% white, 41% T3/4 disease, 39% RT alone, 27% induction chemotherapy, 52% concurrent, and 18% both, and 96% IMRT. Median age at RT was 71 yrs. (range: 65–85); median time from RT to MDASI-HN was 46 mos. (2/3 > 24 mos.). The top 5 MDASI-HN items rated most severe in terms of mean (±SD) ratings (0–10 scale) were dry mouth (3.48 ± 2.95), taste (2.81 ± 3.29), swallowing (2.59 ± 2.96), mucus in mouth/throat (2.04 ± 2.68), and choking (1.30 ± 2.38) reported at moderate-severe levels (≥5) by 35, 29, 29, 18, and 13%, respectively. Thirty-nine % reported none (0) or no more than mild (1–4) symptoms across all 22 MDASI-HN symptoms items, and 38% had at least one item rated as severe (≥7). Hierarchical cluster analysis resulted in 3 patient groups: 1) ~65% with ranging from none to moderate symptom burden, 2) ~35% with moderate-severe ratings for a subset of classically RT-related symptoms (e.g. dry mouth, mucus, swallowing) and 3) 2 pts. with severe ratings of most items.

Conclusions

The overall long-term symptom burden seen in this older OPC cohort treated with modern standard therapy was largely favorable, yet a higher symptom group (~35%) with a distinct pattern of mostly local and classically RT-related symptoms was identified.
Literature
1.
Zumsteg ZS, Lok BH, Ho AS, Drill E, Zhang Z, Riaz N, et al. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. Cancer. 2017;123(8):1345–53.CrossRefPubMed
2.
Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40.CrossRefPubMed
3.
Garden AS, Dong L, Morrison WH, Stugis EM, Glisson BS, Frank SJ, et al. Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:941–7.CrossRefPubMed
4.
Ludbrook JJS, Truong PT, MacNeil MV, Lesperance M, Webber A, Joe H, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys. 2003;55:1321–30.CrossRefPubMed
5.
Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. Eur J Cancer. 2016;68:125–33.CrossRefPubMedPubMedCentral
6.
Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States. Emerg Infect Dis. 2014;20(5):822–8.CrossRefPubMedPubMedCentral
7.
Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–9.CrossRefPubMedPubMedCentral
8.
Sansoni ER, Gross ND. The role of Transoral robotic surgery in the Management of Oropharyngeal Squamous Cell Carcinoma: a current review. Curr Oncol Rep. 2015;17(3):432.CrossRefPubMed
9.
Bøje CR, Dalton SO, Primdahl H, Kristensen CA, Andersen E, Johansen J, et al. Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. Radiother Oncol. 2014;110:91–7.CrossRefPubMed
10.
List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer. 1996;77(11):2294–301.CrossRefPubMed
11.
Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2015;91:925–33.CrossRefPubMedPubMedCentral
12.
Hutcheson KA, Abualsamh AR, Sosa A, Weber RS, Beadle BM, Sturgis EM, et al. Impact of selective neck dissection on chronic dysphagia after chemo-intensity-modulated radiotherapy for oropharyngeal carcinoma. Head Neck. 2016;38:886–93.CrossRefPubMed
13.
Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923–31.CrossRefPubMed
14.
Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, et al. The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced Mucositis. Int J Radiat Oncol Biol Phys. 2008;72:1355–61.CrossRefPubMed
15.
Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, et al. Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer CenterSymptom Inventory-Head and Neck Module. Cancer. 2014;120(13):1975–84.CrossRefPubMedPubMedCentral
16.
Gunn GB, Hansen CC, Garden AS, Fuller CD, Mohamed ASR, Morrison WH, et al. Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: results from a symptom assessment study. Radiother Oncol. 2015;117(1):132–8.CrossRefPubMedPubMedCentral
17.
Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
18.
Chen AM, Farwell DG, Luu Q, Vazquez EG, Lau DH, Purdy JA. Intensity-modulated radiotherapy is associated with improved global quality of life among long-term survivors of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;84:170–5.CrossRefPubMed
19.
Hunter KU, Schipper M, Feng FY, Lyden T, Haxer M, Murdoch-Kinch CA, et al. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes. Int J Radiat Oncol Biol Phys. 2013;85:935–40.CrossRefPubMed
20.
Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, et al. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016;122:1533–43.CrossRefPubMed
21.
Schaefer EW, Hollenbeak CS. Age and stage as determinants of treatment for oral cavity and Oropharyngeal cancers in the elderly David. Oral Oncol. 2015;50:976–82.
22.
Boje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma - a systematic review. Radiother Oncol. 2014;110(1):81–90.CrossRefPubMed
23.
Koppie TM, Serio AM, Vickers AJ, Vora K, Dalbagni G, Donat SM, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112(11):2384–92.CrossRefPubMed
24.
Sio TT, Lin H-K, Shi Q, Gunn GB, Cleeland CS, Lee JJ, et al. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for Oropharyngeal cancer: first comparative results of patient-reported outcomes. Int J Radiat Oncol Biol Phys. 2016;95(4):1107–14.CrossRefPubMedPubMedCentral
25.
Garden AS, Gunn GB, Hessel A, Beadle BM, Ahmed S, El-Naggar AK, et al. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014;120(19):3082–8.CrossRefPubMedPubMedCentral
26.
Selek U, Garden AS, Morrison WH, El-Naggar AK, Rosenthal DI, Ang KK. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys. 2004;59(3):743–51.CrossRefPubMed